Infergen Promotion Produced By Third Party Lands Kadmon In Hot Water With DDMAC
This article was originally published in The Pink Sheet Daily
FDA's Division of Drug Marketing, Advertising and Communications cites Kadmon for failing to include risk information and overstating efficacy in a "STATgram" promoting its hepatitis C treatment interferon alfacon-1.
You may also be interested in...
FDA tells Kadmon Pharmaceuticals that it can’t promote convenience advantages, however factual, as clinical benefits without adequate and well-controlled studies.
The prospect of anemic Medicare compensation for Feraheme (ferumoxytol) may have pushed the company to promote the drug in ways that FDA's advertising reviewers think is illegitimate.
Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.